# Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

> **NCT05384821** · PHASE1,PHASE2 · RECRUITING · sponsor: **Centre Oscar Lambret** · enrollment: 28 (estimated)

## Conditions studied

- Wilms Tumor

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Etoposide
- **DRUG:** Cis-Retinoic acid

## Key facts

- **NCT ID:** NCT05384821
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-14
- **Primary completion:** 2028-05
- **Final completion:** 2028-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05384821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05384821, "Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05384821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*